Daily Anesthesiology Research Analysis
Today’s top anesthesiology-relevant papers span acute care decision-making, anesthesia neuroscience, and perioperative optimization. A multinational study validated simple termination-of-resuscitation rules for in-hospital cardiac arrest, a mechanistic study identified medial prefrontal cortical somatostatin neurons as enhancers of sevoflurane anesthesia, and a randomized trial showed ERAS protocols improve recovery after transvaginal pelvic floor surgery in older adults.
Summary
Today’s top anesthesiology-relevant papers span acute care decision-making, anesthesia neuroscience, and perioperative optimization. A multinational study validated simple termination-of-resuscitation rules for in-hospital cardiac arrest, a mechanistic study identified medial prefrontal cortical somatostatin neurons as enhancers of sevoflurane anesthesia, and a randomized trial showed ERAS protocols improve recovery after transvaginal pelvic floor surgery in older adults.
Research Themes
- Resuscitation decision tools and prognostication
- Neural circuits of anesthesia and consciousness
- Enhanced Recovery After Surgery (ERAS) in older adults
Selected Articles
1. Termination of Resuscitation Rules for In-Hospital Cardiac Arrest.
Using national registries from Denmark (derivation) and Sweden/Norway (validation), five in-hospital termination-of-resuscitation (TOR) rules were developed. The best rule (unwitnessed, unmonitored, asystole, ≥10 min resuscitation) identified 11% of arrests for termination with a 0.6% false-positive rate for 30-day mortality across all cohorts.
Impact: Provides externally validated, bedside-applicable TOR rules with extremely low false positives, addressing a major evidence gap in in-hospital cardiac arrest decision-making.
Clinical Implications: Clinicians (including anesthesiologists/ICU teams) can consider implementing the best-performing TOR rule to guide real-time decisions, reduce futile resuscitation, and standardize practice while safeguarding against premature termination.
Key Findings
- Among 53,864 rule combinations, five TOR rules met prespecified performance criteria and were clinically usable.
- The best rule (unwitnessed, unmonitored, asystole, resuscitation ≥10 minutes) achieved a positive rate of 11% and a false-positive rate of 0.6% for predicting 30-day mortality.
- Performance was consistent across external validation cohorts from Sweden and Norway, supporting generalizability.
Methodological Strengths
- Large, multinational external validation across three national registries
- Use of simple, bedside-available variables with prespecified thresholds for acceptable performance
Limitations
- Observational registry data may be subject to unmeasured confounding and misclassification
- Ethical, legal, and institutional variations may affect implementation and clinician adherence
Future Directions: Prospective implementation studies to assess workflow integration, clinician adherence, patient/family communication, and outcomes; exploration of integration with real-time EHR/CPR dashboards.
IMPORTANCE: There are no validated decision rules for terminating resuscitation during in-hospital cardiac arrest. Decision rules may guide termination and prevent inappropriate early termination of resuscitation. OBJECTIVE: To develop and validate termination of resuscitation rules for in-hospital cardiac arrest. DESIGN, SETTING, AND PARTICIPANTS: In this prognostic study, potential decision rules were developed using a national in-hospital cardiac arrest registry from Denmark (data from 2017 to 2022) and validated using registries from Sweden (data from 2007 to 2021) and Norway (data from 2021 to 2022). Six variables (age, initial rhythm, witnessed status, monitored status, intensive care unit location, and resuscitation duration) were considered based on their bedside availability. Prognostic metrics were computed for all possible variable combinations. CIs were obtained using bootstrapping. Rules with a false-positive rate below 1% (predicting death in patients who might otherwise survive) and a positive rate of more than 10% (proportion of all cases for whom termination is proposed) were considered appropriate. MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day mortality. RESULTS: The cohorts included 9863 Danish, 12 781 Swedish, and 1308 Norwegian patients. The overall median (IQR) age was 74 (66-81) years, 63% were male, and the median (IQR) resuscitation duration was 13 (5-23) minutes. Of 53 864 possible termination rules, 5 were identified as relevant for clinical use. The best performing rule included 4 variables (unwitnessed, unmonitored, initial rhythm of asystole, and resuscitation duration more than or equal to 10 minutes). The rule proposed termination in 110 per 1000 cardiac arrests (positive rate, 11%; 95% CI, 10%-11%) and predicted 30-day mortality incorrectly in 6 per 1000 cases (false-positive rate, 0.6%; 95% CI, 0.3%-0.9%). All 5 rules performed similarly across all 3 cohorts. CONCLUSIONS AND RELEVANCE: In this prognostic study, 5 termination of resuscitation rules were developed and validated for in-hospital cardiac arrest. The best performing rule had a low false-positive rate and a reasonable positive rate in all national cohorts. These termination of resuscitation rules may aid decision-making during resuscitation.
2. Somatostatin-expressing Neurons in the Medial Prefrontal Cortex Promote Sevoflurane Anesthesia in Mice.
In mice, medial prefrontal somatostatin interneurons (SST-INs) are activated during sevoflurane anesthesia. Chemogenetic manipulation of SST-INs bidirectionally altered recovery time, and SST activation increased time-locked GABA input while suppressing pyramidal calcium signals. Increased GABA input preceded loss of righting, indicating a causal cortical microcircuit mechanism enhancing anesthetic effect.
Impact: Provides causal, circuit-level evidence linking cortical inhibitory interneurons to anesthetic-induced unconsciousness, informing mechanistic anesthesia research and potential cortical targets.
Clinical Implications: While preclinical, these data support cortical microcircuit contributions to anesthetic depth, potentially guiding EEG biomarkers and strategies for individualized anesthesia or emergence modulation.
Key Findings
- SST-IN c-Fos expression increased during sevoflurane (26.4% vs 48.0%; P=0.0007).
- Chemogenetic inhibition/activation of SST-INs shortened (84→51 s; P=0.008) or prolonged (97→140 s; P=0.006) recovery from sevoflurane.
- GABA input to pyramidal neurons rose before loss of righting (0.46%→2.25%; P=0.031), and SST activation reduced pyramidal Ca signals (−0.14%→−10.08%; P=0.002).
Methodological Strengths
- Multimodal approach combining EEG, fiber photometry, immunostaining, chemogenetics, and optogenetics
- Time-locked measurements demonstrating causality between SST activity, GABA input, and behavioral endpoints
Limitations
- Mouse model limits direct clinical generalizability
- Focused on sevoflurane; cross-anesthetic generalization remains to be established
Future Directions: Map upstream/downstream SST-IN circuits, test other anesthetics, and translate to human biomarkers (EEG features) for cortical inhibitory tone during anesthesia.
BACKGROUND: The medial prefrontal cortex plays a crucial role in regulating consciousness. However, the specific functions of its excitatory and inhibitory networks during anesthesia remain uncertain. Here, the authors explored the hypothesis that somatostatin interneurons in the medial prefrontal cortex enhance the effects of sevoflurane anesthesia by increasing γ-aminobutyric acid (GABA) transmission to pyramidal neurons. METHODS: Electroencephalography was utilized to reflect the depth of anesthesia. Immunostaining and fiber photometry were employed to assess neuronal activities and GABA delivery. The regulation of neuronal activity was achieved by chemogenetics and optogenetics. RESULTS: The expression of c-Fos was increased in somatostatin neurons of the medial prefrontal cortex during sevoflurane anesthesia (air vs. sevoflurane: 26.4 ± 6.5% vs. 48 ± 6.2%; P = 0.0007; n = 5 mice). Chemogenetic inhibition or activation of somatostatin neurons in the medial prefrontal cortex reduced (from 84 ± 24 s to 51 ± 18 s; P = 0.008; n = 7 mice) or prolonged (from 97 ± 31 s to 140 ± 30 s; P = 0.006; n = 7 mice) the sevoflurane anesthesia recovery time. Increased GABA input to pyramidal neurons in the medial prefrontal cortex precedes sevoflurane-induced loss of consciousness (baseline vs . pre-loss of the righting reflex: from 0.46 ± 0.57% to 2.25 ± 1.42%; P = 0.031; n = 10 mice). Activation of somatostatin neurons in the medial prefrontal cortex leads to a significant reduction in calcium signals within local pyramidal neurons (baseline vs . 20 Hz stimulation: from -0.14 ± 0.52% to -10.08 ± 4.44%; P = 0.002; n = 10 mice). Additionally,GABA input on pyramidal neurons increased (baseline vs . 20 Hz stimulation: from -0.001 ± 0.001% to 0.28 ± 0.03%; P = 0.002; n = 7 mice) in a time-locked manner. Chemogenetic inhibition of pyramidal neurons prolonged the recovery from sevoflurane anesthesia in mice (from 101 ± 46 s to 136 ± 54 s; P = 0.017; n = 19 mice). CONCLUSIONS: Cortical somatostatin neurons may inhibit local pyramidal neurons by enhancing GABA transmission, which increases the effectiveness of sevoflurane anesthesia.
3. Effect of enhanced recovery after surgery on older patients undergoing transvaginal pelvic floor reconstruction surgery: a randomised controlled trial.
In a randomized trial of 100 older adults undergoing transvaginal pelvic floor reconstruction, ERAS reduced postoperative length of stay (median 74→65 hours), accelerated time to first oral intake, lowered pain up to 7 days, shortened airway support duration, reduced PONV at 12 hours, and enabled opioid-sparing versus conventional care.
Impact: Provides prospective randomized evidence supporting ERAS in an older, gynecologic pelvic floor population, a group with high vulnerability to postoperative complications.
Clinical Implications: Adoption of ERAS pathways in older patients undergoing transvaginal pelvic floor reconstruction can shorten LOS, reduce pain and PONV, and decrease opioid exposure without apparent safety concerns.
Key Findings
- Postoperative LOS reduced from 74.00 (69.00–96.00) to 65.00 (59.00–78.25) hours (P<0.01) with ERAS.
- Time to first oral intake shortened (5.00→3.00 hours; P=0.01) and pain decreased up to 7 days post-op.
- Reduced PONV at 12 hours and opioid-sparing with shorter laryngeal mask airway support in ERAS group.
Methodological Strengths
- Randomized controlled design in a defined older surgical population
- Multiple patient-centered recovery endpoints (LOS, pain, PONV, airway support, opioid usage)
Limitations
- Single-center study with modest sample size (N=100)
- Retrospective trial registration may introduce reporting bias
Future Directions: Multicenter trials powered for complications and cost-effectiveness; evaluation of ERAS components and adherence in frail subgroups and long-term functional outcomes.
BACKGROUND: Prospective trial evidence is lacking regarding the application of enhanced recovery after surgery (ERAS) in transvaginal pelvic floor reconstruction surgery among older patients. Our study aimed to investigate whether implementing the ERAS protocol could enhance post-operative recovery in this patient population. METHODS: Older patients undergoing elective transvaginal pelvic floor reconstruction surgery were randomly assigned to either the ERAS group or the conventional group. The primary outcome was post-operative length of stay (LOS). The secondary outcomes encompassed other post-operative recovery metrics, post-operative pain within 30 days, the occurrence of complications, the peri-operative blood test and cognitive function. RESULTS: A cohort of 100 patients was enrolled. Implementation of the ERAS protocol significantly reduced the duration of post-operative LOS (74.00 (69.00, 96.00) vs. 65.00 (59.00, 78.25) h, P < 0.01). Additionally, the ERAS protocol significantly reduced the duration of the first oral intake post-operatively (5.00 (2.50, 7.00) vs. 3.00 (2.00, 4.00) h, P = 0.01), and reduced rest and movement-related pain within 48 h post-operatively, effects that persisted through the 7-day follow-up period. It also shortened the duration of post-operative laryngeal mask airway support and promoted opioid-sparing. Moreover, the incidence and severity of post-operative nausea and vomiting (PONV) were significantly lower in the ERAS group compared to the conventional group at 12 h post-operatively. CONCLUSIONS: Implementation of the ERAS protocol can expedite post-operative recovery in older patients undergoing transvaginal pelvic floor reconstruction surgery, achieve opioid-sparing, alleviate pain post-operatively, and decrease the incidence of complications. TRIAL REGISTRATION: This study was retrospectively registered with the Chinese Clinical Trial Registry (registration number: ChiCTR2400084608). The date of first registration was 21/05/2024.